NEJM:药物干预可有效降低心力衰竭猝死风险

2017-07-06 zhangfan MedSci原创

研究发现对于射血分数降低的心衰患者,进入临床试验后患者猝死率显著下降,这一发现循证了药物治疗对心衰死亡的累积益处

目前有症状的心力衰竭患者猝死的风险随着治疗手段的发展发生了变化。临床治疗中通过血管紧张素转换酶抑制剂、血管紧张素受体拮抗剂、β-受体阻滞剂和盐皮质激素受体拮抗剂的序贯用药可有效控制患者射血分数。近日研究人员对于心衰猝死的变化趋势进行了详细研究。研究人员对1995-2014年间,12个临床试验招募的40195名心力衰竭伴射血分数减少患者资料进行分析,在试验时间植入心律转复除颤器的患者被排除在外。采用加权多变量回归分析研究了猝死率随时间的变化趋势。使用Cox回归模型计算每个试验组猝死的调整危险比。在不同时间点,根据心衰诊断和时间长短评估猝死的累积发生率。研究期间共发生3583起猝死事件,大部分为高龄以及女性患者,多数伴有缺血性心力衰竭并且心脏功能较差。试验患者的猝死率下降了44%(P=0.03),其中患者的90天的累积猝死发生率在最早的试验中为2.4%,最近一次试验为1%。新近诊断的心衰患者其猝死率不高于长期心衰患者。研究发现对于射血分数降低的心衰患者,进入临床试验后患者猝死率显著下降,这一发现循证了药物治疗对心衰死亡的累积益处。原始出处:Li Shen et al. Declining

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1640758, encodeId=42ed1640e5891, content=<a href='/topic/show?id=73b88e73171' target=_blank style='color:#2F92EE;'>#药物干预#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87731, encryptionId=73b88e73171, topicName=药物干预)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de0e22719928, createdName=ms6980045490879608, createdTime=Mon Jul 17 08:54:00 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542919, encodeId=191615429193b, content=<a href='/topic/show?id=a93d681e1ff' target=_blank style='color:#2F92EE;'>#猝死风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68171, encryptionId=a93d681e1ff, topicName=猝死风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=921913505832, createdName=ms3323097325231039, createdTime=Fri Jul 07 20:54:00 CST 2017, time=2017-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219104, encodeId=52e521910448, content=学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Thu Jul 06 09:24:06 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219070, encodeId=2acd2190e065, content=学习了 谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K0iaeHUsbIzwsociaXY4eY8DryoMrt2gEdB9WBJl32NBRdY2JLRtDPibf3KoIM53fldicMJYbSUWVaXU/0, createdBy=e6fc75818, createdName=maymoon1983, createdTime=Thu Jul 06 07:56:17 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219026, encodeId=a3772190266c, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Thu Jul 06 07:06:53 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219024, encodeId=123a21902422, content=一起来讨论吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/03/04d9b9f3fcb2c24e0534b0a7de83c72e.jpg, createdBy=75672052751, createdName=月吟凤歌, createdTime=Thu Jul 06 07:03:52 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219023, encodeId=35b8219023d5, content=优质资源,共同学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K0LqDY57Aia0TOQByoJhNt3icm4sfukp500hLH6RHOpFdV01NbECtAV7s0qKpQPibyRukQAwAmqJU3X/0, createdBy=f91f1928792, createdName=九九消寒, createdTime=Thu Jul 06 06:53:49 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219020, encodeId=1feb21902079, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfDEeydJz0GlP8O0ngrUX6AYCXFic0XDOOAyeQicIqnOd4TrWSwiagJrsFNYuWC1Uc6iavbS1hWt9xtZAhAqLGHqZyl/0, createdBy=42891977006, createdName=1e17414fm02(暂无匿称), createdTime=Thu Jul 06 06:43:56 CST 2017, time=2017-07-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1640758, encodeId=42ed1640e5891, content=<a href='/topic/show?id=73b88e73171' target=_blank style='color:#2F92EE;'>#药物干预#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87731, encryptionId=73b88e73171, topicName=药物干预)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de0e22719928, createdName=ms6980045490879608, createdTime=Mon Jul 17 08:54:00 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542919, encodeId=191615429193b, content=<a href='/topic/show?id=a93d681e1ff' target=_blank style='color:#2F92EE;'>#猝死风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68171, encryptionId=a93d681e1ff, topicName=猝死风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=921913505832, createdName=ms3323097325231039, createdTime=Fri Jul 07 20:54:00 CST 2017, time=2017-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219104, encodeId=52e521910448, content=学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Thu Jul 06 09:24:06 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219070, encodeId=2acd2190e065, content=学习了 谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K0iaeHUsbIzwsociaXY4eY8DryoMrt2gEdB9WBJl32NBRdY2JLRtDPibf3KoIM53fldicMJYbSUWVaXU/0, createdBy=e6fc75818, createdName=maymoon1983, createdTime=Thu Jul 06 07:56:17 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219026, encodeId=a3772190266c, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Thu Jul 06 07:06:53 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219024, encodeId=123a21902422, content=一起来讨论吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/03/04d9b9f3fcb2c24e0534b0a7de83c72e.jpg, createdBy=75672052751, createdName=月吟凤歌, createdTime=Thu Jul 06 07:03:52 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219023, encodeId=35b8219023d5, content=优质资源,共同学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K0LqDY57Aia0TOQByoJhNt3icm4sfukp500hLH6RHOpFdV01NbECtAV7s0qKpQPibyRukQAwAmqJU3X/0, createdBy=f91f1928792, createdName=九九消寒, createdTime=Thu Jul 06 06:53:49 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219020, encodeId=1feb21902079, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfDEeydJz0GlP8O0ngrUX6AYCXFic0XDOOAyeQicIqnOd4TrWSwiagJrsFNYuWC1Uc6iavbS1hWt9xtZAhAqLGHqZyl/0, createdBy=42891977006, createdName=1e17414fm02(暂无匿称), createdTime=Thu Jul 06 06:43:56 CST 2017, time=2017-07-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1640758, encodeId=42ed1640e5891, content=<a href='/topic/show?id=73b88e73171' target=_blank style='color:#2F92EE;'>#药物干预#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87731, encryptionId=73b88e73171, topicName=药物干预)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de0e22719928, createdName=ms6980045490879608, createdTime=Mon Jul 17 08:54:00 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542919, encodeId=191615429193b, content=<a href='/topic/show?id=a93d681e1ff' target=_blank style='color:#2F92EE;'>#猝死风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68171, encryptionId=a93d681e1ff, topicName=猝死风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=921913505832, createdName=ms3323097325231039, createdTime=Fri Jul 07 20:54:00 CST 2017, time=2017-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219104, encodeId=52e521910448, content=学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Thu Jul 06 09:24:06 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219070, encodeId=2acd2190e065, content=学习了 谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K0iaeHUsbIzwsociaXY4eY8DryoMrt2gEdB9WBJl32NBRdY2JLRtDPibf3KoIM53fldicMJYbSUWVaXU/0, createdBy=e6fc75818, createdName=maymoon1983, createdTime=Thu Jul 06 07:56:17 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219026, encodeId=a3772190266c, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Thu Jul 06 07:06:53 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219024, encodeId=123a21902422, content=一起来讨论吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/03/04d9b9f3fcb2c24e0534b0a7de83c72e.jpg, createdBy=75672052751, createdName=月吟凤歌, createdTime=Thu Jul 06 07:03:52 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219023, encodeId=35b8219023d5, content=优质资源,共同学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K0LqDY57Aia0TOQByoJhNt3icm4sfukp500hLH6RHOpFdV01NbECtAV7s0qKpQPibyRukQAwAmqJU3X/0, createdBy=f91f1928792, createdName=九九消寒, createdTime=Thu Jul 06 06:53:49 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219020, encodeId=1feb21902079, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfDEeydJz0GlP8O0ngrUX6AYCXFic0XDOOAyeQicIqnOd4TrWSwiagJrsFNYuWC1Uc6iavbS1hWt9xtZAhAqLGHqZyl/0, createdBy=42891977006, createdName=1e17414fm02(暂无匿称), createdTime=Thu Jul 06 06:43:56 CST 2017, time=2017-07-06, status=1, ipAttribution=)]
    2017-07-06 执着追梦

    学习,谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1640758, encodeId=42ed1640e5891, content=<a href='/topic/show?id=73b88e73171' target=_blank style='color:#2F92EE;'>#药物干预#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87731, encryptionId=73b88e73171, topicName=药物干预)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de0e22719928, createdName=ms6980045490879608, createdTime=Mon Jul 17 08:54:00 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542919, encodeId=191615429193b, content=<a href='/topic/show?id=a93d681e1ff' target=_blank style='color:#2F92EE;'>#猝死风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68171, encryptionId=a93d681e1ff, topicName=猝死风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=921913505832, createdName=ms3323097325231039, createdTime=Fri Jul 07 20:54:00 CST 2017, time=2017-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219104, encodeId=52e521910448, content=学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Thu Jul 06 09:24:06 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219070, encodeId=2acd2190e065, content=学习了 谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K0iaeHUsbIzwsociaXY4eY8DryoMrt2gEdB9WBJl32NBRdY2JLRtDPibf3KoIM53fldicMJYbSUWVaXU/0, createdBy=e6fc75818, createdName=maymoon1983, createdTime=Thu Jul 06 07:56:17 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219026, encodeId=a3772190266c, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Thu Jul 06 07:06:53 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219024, encodeId=123a21902422, content=一起来讨论吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/03/04d9b9f3fcb2c24e0534b0a7de83c72e.jpg, createdBy=75672052751, createdName=月吟凤歌, createdTime=Thu Jul 06 07:03:52 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219023, encodeId=35b8219023d5, content=优质资源,共同学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K0LqDY57Aia0TOQByoJhNt3icm4sfukp500hLH6RHOpFdV01NbECtAV7s0qKpQPibyRukQAwAmqJU3X/0, createdBy=f91f1928792, createdName=九九消寒, createdTime=Thu Jul 06 06:53:49 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219020, encodeId=1feb21902079, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfDEeydJz0GlP8O0ngrUX6AYCXFic0XDOOAyeQicIqnOd4TrWSwiagJrsFNYuWC1Uc6iavbS1hWt9xtZAhAqLGHqZyl/0, createdBy=42891977006, createdName=1e17414fm02(暂无匿称), createdTime=Thu Jul 06 06:43:56 CST 2017, time=2017-07-06, status=1, ipAttribution=)]
    2017-07-06 maymoon1983

    学习了 谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1640758, encodeId=42ed1640e5891, content=<a href='/topic/show?id=73b88e73171' target=_blank style='color:#2F92EE;'>#药物干预#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87731, encryptionId=73b88e73171, topicName=药物干预)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de0e22719928, createdName=ms6980045490879608, createdTime=Mon Jul 17 08:54:00 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542919, encodeId=191615429193b, content=<a href='/topic/show?id=a93d681e1ff' target=_blank style='color:#2F92EE;'>#猝死风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68171, encryptionId=a93d681e1ff, topicName=猝死风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=921913505832, createdName=ms3323097325231039, createdTime=Fri Jul 07 20:54:00 CST 2017, time=2017-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219104, encodeId=52e521910448, content=学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Thu Jul 06 09:24:06 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219070, encodeId=2acd2190e065, content=学习了 谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K0iaeHUsbIzwsociaXY4eY8DryoMrt2gEdB9WBJl32NBRdY2JLRtDPibf3KoIM53fldicMJYbSUWVaXU/0, createdBy=e6fc75818, createdName=maymoon1983, createdTime=Thu Jul 06 07:56:17 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219026, encodeId=a3772190266c, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Thu Jul 06 07:06:53 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219024, encodeId=123a21902422, content=一起来讨论吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/03/04d9b9f3fcb2c24e0534b0a7de83c72e.jpg, createdBy=75672052751, createdName=月吟凤歌, createdTime=Thu Jul 06 07:03:52 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219023, encodeId=35b8219023d5, content=优质资源,共同学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K0LqDY57Aia0TOQByoJhNt3icm4sfukp500hLH6RHOpFdV01NbECtAV7s0qKpQPibyRukQAwAmqJU3X/0, createdBy=f91f1928792, createdName=九九消寒, createdTime=Thu Jul 06 06:53:49 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219020, encodeId=1feb21902079, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfDEeydJz0GlP8O0ngrUX6AYCXFic0XDOOAyeQicIqnOd4TrWSwiagJrsFNYuWC1Uc6iavbS1hWt9xtZAhAqLGHqZyl/0, createdBy=42891977006, createdName=1e17414fm02(暂无匿称), createdTime=Thu Jul 06 06:43:56 CST 2017, time=2017-07-06, status=1, ipAttribution=)]
    2017-07-06 往日如昨

    学习了谢谢分享

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1640758, encodeId=42ed1640e5891, content=<a href='/topic/show?id=73b88e73171' target=_blank style='color:#2F92EE;'>#药物干预#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87731, encryptionId=73b88e73171, topicName=药物干预)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de0e22719928, createdName=ms6980045490879608, createdTime=Mon Jul 17 08:54:00 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542919, encodeId=191615429193b, content=<a href='/topic/show?id=a93d681e1ff' target=_blank style='color:#2F92EE;'>#猝死风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68171, encryptionId=a93d681e1ff, topicName=猝死风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=921913505832, createdName=ms3323097325231039, createdTime=Fri Jul 07 20:54:00 CST 2017, time=2017-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219104, encodeId=52e521910448, content=学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Thu Jul 06 09:24:06 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219070, encodeId=2acd2190e065, content=学习了 谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K0iaeHUsbIzwsociaXY4eY8DryoMrt2gEdB9WBJl32NBRdY2JLRtDPibf3KoIM53fldicMJYbSUWVaXU/0, createdBy=e6fc75818, createdName=maymoon1983, createdTime=Thu Jul 06 07:56:17 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219026, encodeId=a3772190266c, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Thu Jul 06 07:06:53 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219024, encodeId=123a21902422, content=一起来讨论吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/03/04d9b9f3fcb2c24e0534b0a7de83c72e.jpg, createdBy=75672052751, createdName=月吟凤歌, createdTime=Thu Jul 06 07:03:52 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219023, encodeId=35b8219023d5, content=优质资源,共同学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K0LqDY57Aia0TOQByoJhNt3icm4sfukp500hLH6RHOpFdV01NbECtAV7s0qKpQPibyRukQAwAmqJU3X/0, createdBy=f91f1928792, createdName=九九消寒, createdTime=Thu Jul 06 06:53:49 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219020, encodeId=1feb21902079, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfDEeydJz0GlP8O0ngrUX6AYCXFic0XDOOAyeQicIqnOd4TrWSwiagJrsFNYuWC1Uc6iavbS1hWt9xtZAhAqLGHqZyl/0, createdBy=42891977006, createdName=1e17414fm02(暂无匿称), createdTime=Thu Jul 06 06:43:56 CST 2017, time=2017-07-06, status=1, ipAttribution=)]
    2017-07-06 月吟凤歌

    一起来讨论吧

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1640758, encodeId=42ed1640e5891, content=<a href='/topic/show?id=73b88e73171' target=_blank style='color:#2F92EE;'>#药物干预#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87731, encryptionId=73b88e73171, topicName=药物干预)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de0e22719928, createdName=ms6980045490879608, createdTime=Mon Jul 17 08:54:00 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542919, encodeId=191615429193b, content=<a href='/topic/show?id=a93d681e1ff' target=_blank style='color:#2F92EE;'>#猝死风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68171, encryptionId=a93d681e1ff, topicName=猝死风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=921913505832, createdName=ms3323097325231039, createdTime=Fri Jul 07 20:54:00 CST 2017, time=2017-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219104, encodeId=52e521910448, content=学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Thu Jul 06 09:24:06 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219070, encodeId=2acd2190e065, content=学习了 谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K0iaeHUsbIzwsociaXY4eY8DryoMrt2gEdB9WBJl32NBRdY2JLRtDPibf3KoIM53fldicMJYbSUWVaXU/0, createdBy=e6fc75818, createdName=maymoon1983, createdTime=Thu Jul 06 07:56:17 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219026, encodeId=a3772190266c, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Thu Jul 06 07:06:53 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219024, encodeId=123a21902422, content=一起来讨论吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/03/04d9b9f3fcb2c24e0534b0a7de83c72e.jpg, createdBy=75672052751, createdName=月吟凤歌, createdTime=Thu Jul 06 07:03:52 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219023, encodeId=35b8219023d5, content=优质资源,共同学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K0LqDY57Aia0TOQByoJhNt3icm4sfukp500hLH6RHOpFdV01NbECtAV7s0qKpQPibyRukQAwAmqJU3X/0, createdBy=f91f1928792, createdName=九九消寒, createdTime=Thu Jul 06 06:53:49 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219020, encodeId=1feb21902079, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfDEeydJz0GlP8O0ngrUX6AYCXFic0XDOOAyeQicIqnOd4TrWSwiagJrsFNYuWC1Uc6iavbS1hWt9xtZAhAqLGHqZyl/0, createdBy=42891977006, createdName=1e17414fm02(暂无匿称), createdTime=Thu Jul 06 06:43:56 CST 2017, time=2017-07-06, status=1, ipAttribution=)]
    2017-07-06 九九消寒

    优质资源,共同学习

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1640758, encodeId=42ed1640e5891, content=<a href='/topic/show?id=73b88e73171' target=_blank style='color:#2F92EE;'>#药物干预#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87731, encryptionId=73b88e73171, topicName=药物干预)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de0e22719928, createdName=ms6980045490879608, createdTime=Mon Jul 17 08:54:00 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542919, encodeId=191615429193b, content=<a href='/topic/show?id=a93d681e1ff' target=_blank style='color:#2F92EE;'>#猝死风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68171, encryptionId=a93d681e1ff, topicName=猝死风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=921913505832, createdName=ms3323097325231039, createdTime=Fri Jul 07 20:54:00 CST 2017, time=2017-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219104, encodeId=52e521910448, content=学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Thu Jul 06 09:24:06 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219070, encodeId=2acd2190e065, content=学习了 谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K0iaeHUsbIzwsociaXY4eY8DryoMrt2gEdB9WBJl32NBRdY2JLRtDPibf3KoIM53fldicMJYbSUWVaXU/0, createdBy=e6fc75818, createdName=maymoon1983, createdTime=Thu Jul 06 07:56:17 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219026, encodeId=a3772190266c, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Thu Jul 06 07:06:53 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219024, encodeId=123a21902422, content=一起来讨论吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/03/04d9b9f3fcb2c24e0534b0a7de83c72e.jpg, createdBy=75672052751, createdName=月吟凤歌, createdTime=Thu Jul 06 07:03:52 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219023, encodeId=35b8219023d5, content=优质资源,共同学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K0LqDY57Aia0TOQByoJhNt3icm4sfukp500hLH6RHOpFdV01NbECtAV7s0qKpQPibyRukQAwAmqJU3X/0, createdBy=f91f1928792, createdName=九九消寒, createdTime=Thu Jul 06 06:53:49 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219020, encodeId=1feb21902079, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfDEeydJz0GlP8O0ngrUX6AYCXFic0XDOOAyeQicIqnOd4TrWSwiagJrsFNYuWC1Uc6iavbS1hWt9xtZAhAqLGHqZyl/0, createdBy=42891977006, createdName=1e17414fm02(暂无匿称), createdTime=Thu Jul 06 06:43:56 CST 2017, time=2017-07-06, status=1, ipAttribution=)]
    2017-07-06 1e17414fm02(暂无匿称)

    学习

    0

相关资讯

JAHA:急性心衰患者的预后营养指数与临床结局的相关性研究

既往研究显示营养状况与心力衰竭患者的临床结局有关。 本次研究旨在评估预后营养指数(PNI)指标的营养状况与急性心力衰竭住院患者的生存率之间的关系。

EUR HEART J:心脏衰竭患者的药物剂量和临床结局之间的关系

尽管有明确的指导建议,但大多数心衰和射血分数降低的(HFrEF)患者没有达到指导原则推荐的治疗剂量。本研究探究HFrEF患者未达到指导原则推荐的治疗剂量(血管紧张素转化酶(ACE)抑制剂、血管紧张素受体阻断剂(ARB)和/或β受体阻滞剂)所引起临床结局特征和治疗指征的偏差。

JAMA:口服铁补充剂能改善心衰合并缺铁患者的运动能力?

2017年5月,发表在《JAMA》的一项由美国科学家进行的IRONOUT HF随机临床试验,发现口服铁补充剂对心衰合并射血分数降低和缺铁患者的运动能力无改善。

JACC:心衰的诊断时间与患者预后的关系

目前,对于长期的慢性心衰而因急性心衰住院的患者与那些近期诊断为心衰的患者在哪些方面有不同尚未明确。近日,在国际心血管权威杂志JACC上发表了一篇旨在探索心衰的长期性对急性心衰患者临床和预后的影响的临床研究。

JACC:恶化的慢性心力衰竭VS.住院治疗期间近期确诊的心力衰竭

长期慢性心力衰竭者因急性心力衰竭而住院的患者与最近确诊为心衰患二者之间的区别目前尚不清楚。评估慢性心力衰竭与急性心力衰竭的病人概况和预后影响

Circulation:心衰患者活动量和预后的相关性研究!

物理活动(PA)与健康人群的不良心血管(CV)预后成反比关系,但是在心脏衰竭患者中,身体的活动量对射血分数(HFpEF)的影响研究还很少。在醛固酮拮抗剂治疗心力衰竭患者的心脏功能不全(Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist ,TOPCAT)临床试验中,本研究选取了175